Lower expression of KAI1 as a biomarker of poor survival prognosis of melanoma combined with colorectal cancer metastasis

J Int Med Res. 2022 Aug;50(8):3000605221116758. doi: 10.1177/03000605221116758.

Abstract

Objective: This study aimed to investigate the correlation between KAI1 (CD82) and miR-633 expression and prognosis and survival time of patients with melanoma combined with colorectal cancer (CRC).

Methods: Clinical and follow-up data of melanoma and CRC patients were recorded, and the expression levels of KAI1 and miR-633 were detected. Pearson chi-square tests and Spearman correlation coefficient were used to analyze the relationship between prognosis and related parameters in these patients. Cox proportional risk regression and receiver operating characteristic curve analyses were used.

Results: Overall, 195 patients were included. KAI1 and miR-633 expression levels were significantly correlated with the prognosis of patients with melanoma combined with CRC. Spearman correlation analysis showed that the expression levels of KAI1 and miR-633 were significantly correlated with the prognosis of patients. Multivariate Cox regression analysis suggested that low expression levels of KAI1 and high expression levels of miR-633 indicated shorter survival time for patients.

Conclusions: KAI1 expression was significantly correlated with melanoma and CRC patient prognosis. When KAI1 expression levels were low, the patient survival time was poor.

Keywords: KAI1; Melanoma; colorectal cancer; miR-633; prognosis; survival time.

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Humans
  • Kangai-1 Protein / analysis
  • Kangai-1 Protein / genetics
  • Kangai-1 Protein / metabolism*
  • Melanoma* / genetics
  • Melanoma* / pathology
  • MicroRNAs* / genetics
  • Neoplasm Staging
  • Prognosis

Substances

  • Biomarkers, Tumor
  • CD82 protein, human
  • Kangai-1 Protein
  • MIRN633 microRNA, human
  • MicroRNAs